Related Experiment Video
Updated: Jun 24, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Inhibitor development: patient-determined risk factors
1Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden. Jan.astermark@med.lu.se
Summary
Understanding why some hemophilia A patients develop factor VIII antibodies is key. Genetic and non-genetic factors influence this immune response, impacting treatment outcomes.
Area of Science:
- Immunology
- Hematology
- Genetics
Background:
- Inhibitory factor VIII antibodies develop in a subset of hemophilia A patients, complicating treatment.
- Patient-related genetic factors significantly influence the immunological response to factor VIII replacement therapy.
- Non-genetic factors and immune system challenges can also modify inhibitor risk.
Purpose of the Study:
- To review genetic factors contributing to inhibitor development in hemophilia A.
- To explore the interaction between genetic and non-genetic factors influencing inhibitor risk.
- To enhance prediction and prevention strategies for factor VIII inhibitor complications.
Main Methods:
- Review of data from unrelated and related subjects in the Malmö International Brother Study (MIBS).
- Analysis of genetic factors associated with inhibitor development.
- Discussion of potential interactions between genetic and non-genetic risk factors.
Main Results:
- Studies in genetically related subjects suggest patient-specific factors are crucial for immune outcomes.
- Non-genetic events can modulate immune responses, affecting inhibitor development.
- The Malmö International Brother Study provides insights into genetic predispositions.
Conclusions:
- Further research into immunological pathways and risk factors is essential for predicting and preventing inhibitor complications.
- Understanding genetic and non-genetic interactions is vital for personalized hemophilia A management.
- Improved prediction and prevention strategies are needed for factor VIII inhibitor development.
Related Concept Videos
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...